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Abstract 
Corneal transplantation is not invariably successful despite the anterior chamber of the eye 
being an immunologically privileged site. Inflammation erodes privilege. Other than by 
reducing inflammation through meticulous surgery, careful postoperative surveillance, and 
effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do 
to improve the outlook for the majority of patients receiving corneal transplants. For patients 
at appreciable risk, HLA Class I matching may help where it is available. So too will 
systemic immunosuppression where it can be justified. Despite these measures, the results of 
corneal transplantation have not shown the improvement seen in solid organ transplantation 
over the last 30 years. New approaches applicable to corneal transplantation are required. 
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Introduction 
Corneal transplantation is often thought of as being highly successful because the cornea and 
anterior chamber of the eye are privileged sites. In some experimental situations, a normal 
cornea grafted into a normal cornea will survive indefinitely. Unfortunately, in clinical 
practice, normal corneas are not grafted into normal recipient beds. The closest a clinician 
comes to this is grafting someone for keratoconus or stromal dystrophy. In these cases, graft 
survival is almost invariably prolonged. However, many patients requiring a corneal graft 
have acquired corneal conditions and for this group of patients, prolonged graft survival 
occurs less frequently. In Australia, only 31% of corneal grafts are performed for keratoconus 
and less than 1% are carried out for stromal dystrophies.1
In patients with acquired corneal disease, immunological privilege is eroded. Erosion of 
corneal privilege leaves the graft prone to allograft rejection, the commonest reason for 
corneal graft failure. The degree of erosion of privilege is related to the nature of the 
underlying disease. In some conditions and circumstances, the erosion of graft privilege and 
the tendency to allograft rejection is such that graft failure is almost inevitable. In others, the 
erosion is much less and prolonged graft survival can occur but is not invariable. A 
comprehensive evaluation of the clinical factors associated with a higher risk of corneal graft 
failure is made in the regular reports of the Australian Corneal Graft Register and assessed by 
multivariate analysis.
 The majority of corneal transplants 
are carried out for acquired corneal conditions. 
2 The clinical factors shown to be related to the risk of corneal graft 
failure are presented in Table 1. 
Table 1. Variables best predicting corneal graft failure. Summary of the multivariate analysis 
reported in the 1999 report of the Australian Corneal Graft Register 
Indication for graft 
Number of previous ipsilateral grafts 
Eye inflamed at the time of graft 
Graft size 
Lens status immediately after graft 
Neovascularization of the graft 
Occurrence of graft rejection episode 
Microbial keratitis or stitch abscess in the graft 
Early removal of graft sutures 
Postoperative rise in intraocular pressure 
Those for whom the chance of prolonged survival is reduced are considered high-risk 
patients. Just how this high-risk group is defined depends on how high one wishes to put the 
bar. Any patient having a graft for an acquired condition is at a higher risk of failure 
compared to someone having a graft for keratoconus. This risk is much higher if the recipient 
cornea has recently been inflamed, is inflamed at the time of surgery, or subsequently 
becomes inflamed. 
There is some debate as to what constitutes a high-risk corneal graft. This is evident from the 
criteria used to admit patients to treatment trials where there is considerable variation in the 
criteria used. For the purposes of this discussion, we have adopted an arbitrarily determined 
categorization that we use in our clinical practice. It is based on consideration of factors 
shown to be associated with graft survival in the Australian Corneal Graft Register and 
presented in Table 2. 
Table 2. Risk assignment for corneal grafts based on preoperative pathology 
Low risk Keratoconus, stromal dystrophies 
Intermediate 
risk 
Not keratoconus or stromal dystrophy and excluding patients with clinical features 
associated with high risk, for example, most cases of pseudophakic bullous 
keratopathy 
High risk Any one of 
  previous graft failure 
  previous keratitis 
  current keratitis 
  vascularization into recipient bed 
A distinction must be made between a high-risk graft and a patient at high risk. A high-risk 
graft is one that is likely to fail. The risk faced by a patient is a more complicated 
consideration because for a patient the concept of risk entails not only the probability of a 
complication occurring but the consequence of its occurrence. For this reason, one-eyed 
patients are at a higher risk from eye surgery than binocular patients. One also has to take into 
account the consequences of any treatment other than the surgery. Some treatments that may 
be used for patients with high-risk corneal grafts, such as systemic immunosuppression, come 
with significant risks. The management of patients needing corneal transplantation is 
therefore determined by an assessment of the benefits of a successful outcome, of the risk of 
graft failure, and the potential consequences of any supporting therapies that might be 
considered. 
Immune privilege and the corneal allograft response 
Inflammation in the recipient graft bed, or subsequently in the graft, erodes graft rejection 
and predisposes to allograft rejection and graft failure. An appreciation of how inflammation 
erodes corneal privilege and mechanisms of corneal allograft rejection is required as a basis 
for proposing strategies to decrease the impact of immunological rejection on graft survival. 
A number of factors contribute to immunological privilege in the cornea and anterior segment 
of the eye.  
1. The blood–eye barrier. The normal cornea is somewhat remote from the intravascular 
space. Only the most peripheral cornea is directly dependent on circulation for 
nutrition and respiration. The central cornea relies on the tear-film and the aqueous 
humour for its maintenance. The aqueous is supported by the vascular iris, but there is 
no free exchange between the intravascular space and the aqueous. The constituents 
of the aqueous get there by a process of active secretion. This separation of the ocular 
tissues and the intravascular space is referred to as the blood–eye barrier.
2. Absence of blood vessels and lymphatics. The normal cornea is devoid of blood 
vessels and lymphatics. The absence of blood vessels and lymphatics interferes with 
both the afferent and efferent arm of the immune response.
3,4,5 
3. Modest expression of HLA. There is some Class I expression on epithelial cells, 
stromal keratocytes, and corneal endothelial cells. There is also modest Class II 
expression on Langerhans cells in the peripheral epithelium and interstitial dendritic 
cells in the peripheral stroma.
6,7,25 
8 ABO antigens are present on epithelial cells.9,10
4. Scarcity of antigen processing cells. The normal cornea contains few mature cells 
capable of presenting antigens to the host immune system. There are Langerhans cells 
in the epithelium
 
Transplantation experiments in rats demonstrate that it is the minor antigens that are 
important in the corneal allograft response rather than Class I or II. 
11,12 and interstitial dendritic cells in the peripheral cornea,13,14
5. Constitutive expression of Fas-ligand (CD95L). Only privileged sites constitutively 
express Fas-Ligand. The presence of this entity promotes apoptosis in cells bearing 
Fas, such as immunocytes.
 but 
very few become involved in the operative field with conventional corneal grafting. 
6. Immunosuppressive cytokines in aqueous humour, for example, transforming growth 
factor TGFb,
15,16,17 
18,19 alpha-melanocyte-stimulating hormone MSH,20 and vasoactive 
intestinal peptide VIP 21
7. Anterior chamber-associated immune deviation. Antigens introduced into the anterior 
chamber of the eye produce antigen-specific suppression of delayed 
hypersensitivity.
 present in normal aqueous humor. 
Some of these factors that contribute to the immune privilege in the anterior eye are altered 
by inflammation. Inflammation breaks down the blood–eye barrier. An increase of the 
leakiness of blood vessels is a fundamental aspect of inflammation. Any inflammation in the 
anterior segment of the eye results in egress of cells and proteins into the extravascular 
space.
22 
Chronic inflammation can result in the development of new blood vessels and lymphatics.
23,24 
25 
The presence of new vessels in the cornea is easily seen clinically and is associated with an 
increased risk of corneal allograft rejection.26 
There is also an increased expression of HLA antigens in the cornea under inflammatory 
conditions.27,28 In addition, there is an accumulation of bone-marrow-derived cells in the 
cornea with inflammation.22,25 These cells may persist for many years after an inflammatory 
event. Perhaps the cornea always has higher cell counts after inflammation and never returns 
to normal. The number of bone-marrow-derived cells in the recipient cornea is related to the 
probability of corneal graft failure from rejection.29
There is little a clinician can do to maintain corneal privilege other than suppress 
inflammation. This is made possible by reducing corneal trauma to a minimum, by exemplary 
microsurgical technique, prompt attention to episodes of intercurrent inflammation such as 
blepharitis or loose sutures, and the use of anti-inflammatory medication, particularly topical 
corticosteroids. 
 When corneal graft privilege is 
sufficiently eroded, allograft rejection can occur. 
Mechanisms of corneal allograft rejection 
An idealized model of allograft rejection can be constructed from clinical observations and 
experimental inferences. The process has some important differences from other organ 
systems. 
Both major and minor transplantation antigens seem capable of providing the starting point 
for the corneal allograft response.30 It is the bone-marrow-derived cells, the interstitial 
dendritic cells, that process alloantigens and present them to the host immunocyte. This 
occurs in the ocular environs and local lymph nodes.
The second step in the afferent arm of the corneal allograft response is T-cell activation. This 
occurs when a foreign protein has been digested in fragments within a phagocytic cell and 
presented on the cell surface in conjunction with host HLA molecules to a host naive 
immunocyte. Once activated, an immunocyte can take on a number of activities related to 
immunity, such as regulation of immune responses, delayed-type hypersensitivity reactions, 
and specific lysis of cells. One of the activities of T lymphocytes is the promotion of clonal 
expansion. Clonal expansion occurs in draining lymph nodes, and for the cornea the relevant 
nodes are in the face and the neck.
31,32 
The efferent arm of the corneal allograft response is directed at all components of the cornea, 
but the endothelial cell monolayer is the most susceptible.
32 
33 It has limited capacity for repair. 
Cell damage occurs as a result of mechanisms specifically aimed at cells bearing nonself 
antigens and through nonspecific mechanisms. A summary of the relevant aspects of the 
corneal allograft response is presented in Figure 1. 
 Figure 1: Schematic representation of corneal allograft rejection in the eye and the draining 
lymph nodes. 
Since it is not possible to specifically enhance corneal privilege—only generic strategies to 
minimize inflammation are practical—surgeons are left with abrogating the corneal allograft 
response as the only feasible approach to improve the outlook for patients having high-risk 
corneal grafts. There are only limited options for achieving this: minimizing inflammation, 
reducing relevant immunogenetic differences between donor and host by antigenic matching, 
and by suppressing host immunoreactivity. 
Strategies for decreasing the effect of the corneal allograft response 
Effective anti-inflammatory measures 
Effective microsurgery can reduce postoperative inflammation and so too can the use of 
topical anti-inflammatory measures. The time-honoured way of achieving this is with topical 
corticosteroids. Anecdotal reports suggest that the outcome of corneal transplantation 
improved dramatically with the introduction of these agents in the 1960s. Unfortunately, the 
optimal dose of topical steroids for patients having corneal grafts has not been agreed upon 
and there is considerable variation in the way clinicians use these drugs. The unexpectedly 
good results reported in the Collaborative Corneal Transplantation Study (CCTS)34 in both 
the antigen-matched and control group have been attributed to the high doses of topical 
corticosteroids used in the postoperative period.35
HLA matching 
 This was considered to be higher than used 
by most surgeons in their routine practice. Even when topical corticosteroids are used at close 
to the maximal tolerated dose, they are only partially effective. The rejection rates for high-
risk patients remain unacceptably high despite high doses of topical corticosteroids. 
There is argument about the place of conventional HLA matching for corneal transplantation, 
particularly since the unexpected findings of the CCTS.34 The results of this study have been 
controversial. They reported no advantage from Class I and II matching but a benefit from 
ABO matching. These findings for Class I and II matching contradict earlier studies. This has 
been attributed to a number of factors, including the high doses of topical corticosteroids used 
in the postoperative period and insufficiently accurate tissue typing. The benefit seen with 
ABO matching is real, surprising, and worthy of further investigation. 
Despite the findings of the CCTS the weight of evidence from published studies suggests a 
modest effect for Class I.35,36,37,38,39 The effect of Class II matching is more equivocal and 
there are reports to suggest an inverse response as well as a beneficial response.40,41,42,43
Systemic immunosuppression 
 (An 
inverse response is not completely unexpected since indirect presentation of antigen, as 
occurs in the corneal allograft response, is Class II restricted.) There is also experimental 
evidence that minor antigens are relatively more important than in other forms of clinical 
transplantation. However, even if the modest benefits of matching are to be pursued, the 
logistics of achieving acceptable matches is complicated and time consuming. For many 
patients, the prolonged waiting time for a matched graft is unacceptable considering the 
limited benefits from the process. 
Although systemic immunosuppression is widely used in other forms of clinical 
transplantation, there are only limited reports of the effectiveness of this approach for corneal 
transplantation. The most convincing study demonstrated enhanced graft survival in patients 
who received systemic cyclosporin for a year compared to groups that received it for only 4 
months and a third group that did not receive cyclosporin at all.44,45
There are no large studies to support the use of antiproliferative agents along with systemic 
cyclosporin, an approach used widely in solid organ transplantation. Despite the lack of hard 
evidence, we prefer this approach. The combination of a calcineurin blocker (cyclosporin or 
FK506) and an antiproliferative agent (azothioprine or mycophenolate) is widely used in 
transplantation and has been shown to be more effective than cyclosporin alone. There is no 
particular regimen that has been shown to be preferable for patients with high-risk corneal 
grafts. Nor has the period of time required for immunosuppression to maximize graft survival 
been determined. Our policy has been to use the same regimen that is used for essential organ 
transplantation in our institution. This facilitates prescribing as well as efficacy and toxicity 
surveillance. We use cyclosporin and azothioprine or mycofenolate for 1 year unless the 
drugs are poorly tolerated. 
 Although no major side 
effects were reported in this study, our experience is that virtually all patients who receive 
systemic immunosuppressive doses of the drug develop some drug-related complication. 
There is the risk of developing potentially overwhelming infection, even with short-term use, 
and there is the issue of neoplasia, particularly with long-term administration. Skin and hair 
changes are common, so too is hypertension. With long-term therapy, nephrotoxicity is 
troublesome. 
It must be emphasized that the documented risks associated with this approach are not 
acceptable for many patients having corneal transplants. Since the consequences of 
complications of immunosuppression may be life threatening, this approach is only 
acceptable for patients who are blind for the want of a functioning graft and are prepared to 
risk a potentially fatal outcome to achieve an improvement in vision.
A summary of the options available to surgeons managing patients with high-risk corneal 
transplants is presented in Table 3. 
46 
Table 3. Management of high-risk corneal grafts 
Intervention  Level of evidence  Recommendation  
Topical corticosteroids Established treatment Mainstay of treatment 
  
Indirect evidence from RCT 
that high dose is better than 
low dose 
Use highest tolerable dose, for 
example, prednisolone acetate eye 
drops 1% four times per day 
Antigen matching RCT show limited beneficial effect for Class I 
Class I—use for high-risk cases if 
practical in very high risk cases 
  
Conflicting evidence for Class 
II matching— some evidence 
of inverted result for Class II 
Class II—not advocated 
  
ABO evidence of beneficial 
effect in CCTs. Needs to be 
confirmed by other studies 
ABO—not advocated 
Topical cyclosporine No evidence of effect in several RCT trials Not advocated 
Systemic steroids Controlled studies show prolonged graft survival 
Short-term administration (up to 4 
months) in high-risk cases 
Systemic immunosuppression 
with cyclosporine and 
antiproliferative agent 
Controlled studies confirm 
prolonged graft survival 
Intermediate-term therapy (1 year if 
tolerated) in high-risk cases 
Treatment of corneal allograft rejection—graft retrieval 
Many grafts that are subjected to an allograft response are lost. For those who recover, the 
prospects for long-term survival are reduced.1,2 Rejection episodes are significant events in 
the life of a graft, and demand prompt attention and effective treatment. It has been shown 
that corticosteroids, delivered as an intravenous pulse, retrieve more rejection episodes than 
oral steroids. Whether this form of treatment reduces the tendency for subsequent rejection is 
unknown.
Novel approaches to immunomodulation 
47 
Antibody-based therapies have an established place in most branches of clinical 
transplantation, but have not found a place in corneal transplantation to date. Heterologous 
antilymphocyte serum or globulin has been used for essential solid organ grafts for many 
years. More recently, monoclonal antibodies have been used. OKT3 is used for the treatment 
of allograft rejection in solid organ transplantation. This approach has not found a place in the 
treatment of corneal allograft rejection although one group has reported the use of 
monoclonal antibodies administered by injection into the anterior chamber of the eye.48,49 
More recently, there have been anecdotal reports of monoclonal antibodies, CAMPATH-1H 
(anti-CD52)50,51 and anti-CD25,52
Desirable attributes of any novel therapies for corneal transplantation include increased 
specificity of immune suppression and local administration. To achieve this, any proposed 
interference with the allograft response should be proximal in the afferent limb—at the point 
of antigen processing and generation—with the hope of achieving suppression of the 
response to only the relevant alloantigens. Local administration of therapeutic agents as eye 
drops would also convey advantage. Local administration limits toxicity to the point of 
 given systemically to successfully suppress clinical corneal 
allograft rejection. As promising as these developments are, they bring with them the 
limitations of systemic administration and systemic side effects. 
application, and there are the additional advantages of ease of administration and low cost. 
Two developments that show promise of satisfying these requirements are the development 
of monoclonal antibody fragments directed at targets in the immune system53 and the use of 
gene therapy to modify the allograft response by influencing cytokine production.
Conclusion 
54 
There is room for improvement in the outcome of corneal transplants, particularly for patients 
receiving grafts for conditions other than keratoconus and stromal dystrophies. Corneal 
transplantation has not shown the steady improvements that have been seen in other branches 
of clinical transplantation because the developments in clinical therapies that have brought 
about these improvements are not directly applicable to corneal transplantation. To achieve 
optimal results for corneal transplantation, it is necessary to select cases carefully to ensure 
that patients have the greatest chance of improving their functional (binocular) vision at the 
least personal risk. For the most part, this means avoiding corneal transplantation in patients 
who have normal vision in the contralateral eye. More heroic measures can be considered for 
patients who are blind but for the need of a clear corneal graft. In all patients receiving a 
corneal graft, effective anti-inflammatory measures, and in particular the use of topical 
corticosteroids in the maximal tolerated dose in the postoperative period, are mandatory. 
Matching for Class I antigens is also justified where the service is available and it is 
reasonable for the patient to wait the time predicted to achieve a helpful match. In some 
patients, systemic immunosuppression is desirable. This is a small group of patients with 
clinical features indicating allograft rejection is likely, who are in need of a clear graft to 
achieve functional vision, and who are fit and understand the implications of systemic 
immunosuppression. Even when all these measures are possible, graft failure because of 
allograft rejection, and other nonimmunological processes, still occurs. More research and 
development is needed. Improvements in antigen matching, anti-inflammatory measures, and 
immunomodulation that are applicable to clinical corneal allograft rejection are required. 
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